SenzaGen wins DI’s Gasellsprånget – most promising company to become Supergasell within 5 years

On May 25, SenzaGen was elected winner at the Swedish newspaper Dagens Industri’s event and competition Gasellsprånget, at the national finale in Gothenburg. After a tough round of questions and an audience poll, SenzaGen was elected winner with the greatest market potential and future outlook, leaving the competitor DigiExam a close second.

-SenzaGen has great future potential in a new and growing global market. We have been working very hard which makes it particularly rewarding to receive this award and the attention it creates. We are seeing an increased interest in our technology and I am confident that this award will lead to more exciting business opportunities in Europe and globally, says Anki Malmborg Hager, CEO of SenzaGen.

About Gasellsprånget

Gasellsprånget is a competition highlighting Swedish growth companies on the rise. The competition is hosted by the Swedish newspaper Dagens Industri and is split into several regional competitions, from which two contestants are chosen to participate in the national finale.

"In the selection of finalists for Gasellsprånget 2016, the jury nominated the companies that have the best opportunities to become Supergasell within a 5-year period, based on analysis and on-stage presentations by the competing companies.”

For more information:
Anki Malmborg Hager,
CEO, SenzaGen AB
Phone: +46 768 284822


About Us

About SenzaGen SenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company's patented tests are the most reliable on the market and provide more information than traditional evaluation methods. We ourselves sell the tests in Sweden and the USA, and we sell through partners in several other countries. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in San Francisco, USA. For more information visit About GARD GARD is a group of tests for assessing chemical skin sensitizers. The tests make use of genetic biomarkers for more than 200 genes which cover the entire immune reaction and are relevant to predicting the risk of hypersensitivity. The tests have up to 90% reliability. This compares with the current predominant test method, experiments on mice, which has an accuracy of 70-75%. SenzaGen's tests are also capable of measuring the potency of a substance's allergenic properties. Consequently GARD tests provide a much more comprehensive basis for determining whether a substance should be classified as an allergen than current testing methods.




Documents & Links